FY2025 EPS Estimates for Prothena Reduced by HC Wainwright

Key Points

• HC Wainwright has significantly lowered Prothena's FY2025 earnings per share (EPS) estimate from ($2.78) to ($4.13), maintaining a "Buy" rating with a target price of $14.00.
• Prothena's recent earnings report showed a miss, with EPS of ($1.86) compared to the expected ($1.11).
• Currently, there is a consensus rating of "Hold" for Prothena with a price target averaging $30.25, despite mixed analyst opinions.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Prothena in a research report issued on Tuesday, August 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of ($4.13) for the year, down from their prior estimate of ($2.78). HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena's FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($5.22) EPS, FY2028 earnings at ($2.49) EPS and FY2029 earnings at ($3.34) EPS.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.75). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%. The business had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million.

PRTA has been the topic of a number of other reports. Royal Bank Of Canada decreased their price target on Prothena from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Jefferies Financial Group downgraded Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a research report on Tuesday, May 27th. Oppenheimer cut Prothena from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 27th. Chardan Capital restated a "buy" rating and set a $18.00 price objective on shares of Prothena in a research report on Tuesday, August 5th. Finally, Bank of America reaffirmed an "underperform" rating on shares of Prothena in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Prothena has a consensus rating of "Hold" and a consensus price target of $30.25.

Prothena Trading Down 0.7%

Shares of Prothena stock traded down $0.05 on Thursday, reaching $7.64. 640,660 shares of the company were exchanged, compared to its average volume of 1,061,299. The stock has a fifty day moving average price of $6.20 and a 200-day moving average price of $9.60. The firm has a market capitalization of $411.26 million, a price-to-earnings ratio of -1.36 and a beta of -0.03. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $22.83.

Institutional Investors Weigh In On Prothena

Several large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC raised its stake in shares of Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 833 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Prothena by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company's stock valued at $381,000 after acquiring an additional 1,551 shares during the period. Invesco Ltd. raised its stake in Prothena by 4.0% during the fourth quarter. Invesco Ltd. now owns 42,846 shares of the biotechnology company's stock worth $593,000 after acquiring an additional 1,632 shares in the last quarter. XTX Topco Ltd increased its position in Prothena by 19.9% in the fourth quarter. XTX Topco Ltd now owns 18,665 shares of the biotechnology company's stock worth $259,000 after purchasing an additional 3,101 shares during the period. Finally, Purkiss Capital Advisors LLC boosted its holdings in Prothena by 15.1% during the second quarter. Purkiss Capital Advisors LLC now owns 24,904 shares of the biotechnology company's stock worth $151,000 after buying an additional 3,275 shares during the last quarter. 97.08% of the stock is owned by hedge funds and other institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.